Literature DB >> 3511688

Carcinoembryonic antigen in breast cancer. Clinical review.

D B Beard, C M Haskell.   

Abstract

Carcinoembryonic antigen is widely used as a tumor marker for gastrointestinal neoplasms. Its role in the management of other tumors is poorly defined. This review considers the place of carcinoembryonic antigen measurement in the management of breast cancer and concludes that sufficient data exist to support its use in clinical practice. Of the many potential uses, the major role for carcinoembryonic antigen measurement in breast cancer is in following patients with advanced disease, especially patients with bone metastases.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3511688     DOI： 10.1016/0002-9343(86)90015-x

Source DB:  PubMed          Journal:  Am J Med        ISSN： 0002-9343            Impact factor:   4.965


  12 in total

1.  Serum tumor marker kinetics and the clinical course of patients with advanced breast cancer.

Authors:  H Sonoo; J Kurebayashi
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

Review 2.  The use and potential of serum tumour markers, new and old.

Authors:  S E Bates
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

3.  A suggested guiding panel of seromarkers for efficient discrimination between primary and secondary human hepatocarcinoma.

Authors:  Nabil Mohie Abdel-Hamid; M M Abouzied; M H Nazmy; M A Fawzy; A S Gerges
Journal:  Tumour Biol       Date:  2015-09-19

4.  Progesterone binding cyst protein (PBCP) in primary breast cancer: a new prognostic factor?

Authors:  J A Søreide; O A Lea; S Kvinnsland
Journal:  Breast Cancer Res Treat       Date:  1987       Impact factor: 4.872

5.  Increased serum concentrations of cholesterol and triglycerides in the progression of breast cancer.

Authors:  C C Zielinski; I Stuller; P Rausch; C Müller
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

6.  Markers in breast cancer: does CEA add to the detection by CA 15.3?

Authors:  J C Delarue; H Mouriesse; F Dubois; S Friedman; F May-Levin
Journal:  Breast Cancer Res Treat       Date:  1988-07       Impact factor: 4.872

7.  Placental isoferritin (PLF) in comparison with MCA and CEA in advanced breast cancer--first data from a pilot study.

Authors:  M Stierer; H R Rosen; E Forster; C Moroz
Journal:  Breast Cancer Res Treat       Date:  1991-11       Impact factor: 4.872

8.  Expression of monoclonal-antibody-defined antigens in fractions isolated from human breast carcinomas and patients' serum.

Authors:  M V Croce; M R Price; A Segal-Eiras
Journal:  Cancer Immunol Immunother       Date:  1995-02       Impact factor: 6.968

9.  The usefulness of CA15.3, mucin-like carcinoma-associated antigen and carcinoembryonic antigen in determining the clinical course in patients with metastatic breast cancer.

Authors:  P Deprés-Brummer; M Itzhaki; P J Bakker; F J Hoek; K H Veenhof; R de Wit
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

10.  Comparison of mammary serum antigen (MSA) and CA15-3 levels in the serum of patients with breast cancer.

Authors:  N P Sacks; S A Stacker; C H Thompson; J P Collins; I S Russell; J A Sullivan; I F McKenzie
Journal:  Br J Cancer       Date:  1987-12       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.